Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MetaStat Inc (MTST)
OTHER OTC:MTST
Holding MTST?
Track your performance easily
MTST Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Ownership Overview
0.00%
Insiders
0.00%
Mutual Funds
8.51% Other Institutional Investors
91.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MTST FAQ
What was MetaStat Inc’s price range in the past 12 months?
Currently, no data Available
What is MetaStat Inc’s market cap?
Currently, no data Available
When is MetaStat Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MetaStat Inc’s earnings last quarter?
Currently, no data Available
Is MetaStat Inc overvalued?
According to Wall Street analysts MetaStat Inc’s price is currently Overvalued.
Does MetaStat Inc pay dividends?
MetaStat Inc does not currently pay dividends.
What is MetaStat Inc’s EPS estimate?
MetaStat Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MetaStat Inc have?
MetaStat Inc has 5,877,000 shares outstanding.
What happened to MetaStat Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MetaStat Inc?
Currently, no hedge funds are holding shares in MTST
---
Company Description
MetaStat Inc
MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes MetaSite Breast and MenaCalc platforms. The MetaSite Breast test measures the process of systemic metastasis and is intended for early stage breast cancer patients. The MenaCalc, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is broadly applicable in solid epithelial-based cancers, including breast, prostate, lung and colorectal. The company was founded by Warren C. Lau in July 2009 and is headquartered in Boston, MA.
---
---